SEATTLE CHILDREN'S THERAPEUTICS THERAPEUTIC CELL PRODUCTION CORE COMMUNICATION FORM

Document number: CF-02488-03

Revision: 03

Effective date: 06/30/2023

PLAT-07

MNC COLLECTION FORM: SCRI-CAR22v2			
PATIENT INFORMATION			
LAST NAME FIRST NAME	MIDDLE NAME		
DATE OF BIRTH			
//			
(MM) (DD) (YYYY)			
RECIPIENT MRN or IDENTIFIER: SUBJECT ID: 02488-S			
MNC COLLECTION INFORMATION			
Collection Center Name:			
Date of Collection: Collection End T	Collection End Time: Whole Blood Volume		
/ /		mL	
(MM) (DD) (YYYY)			
Collection Volume + Anticoagulant: Minimum Target Plasma Volume:			
$mL \times 0.3 = mL$			
Date and Time Product Packaged for Transport:			
MNC COLLECTION SUMMARY			
Plasma volume added to MNC Collection bag is at least 30% of Collection Volume + Anticoagulant		□ PASS □ FAIL	
Total MNC product volume does NOT exceed 600mL		□ PASS □ FAIL	
MNC Bag Label affixed to collection bag and all patient identifiers are legible and have been verified		□ PASS □ FAIL	
Proximal seals to the collection bag are hermetic (only heat seals and metal clips are acceptable)		\square PASS \square FAIL	
Anticoagulant was used		\square PASS \square FAIL	
COMMENTS	ID Label		
□ N/A			
	[
	Place Hospital ID Lab	el Here	
OPERATOR INFORMATION			
Completed By:	Date:		

E-MAIL COMPLETED FORM TO <u>TCPC@seattlechildrens.org</u>.
FILE COMPLETED FORM IN CLINICAL SUBJECT STUDY BINDER

SEATTLE CHILDREN'S THERAPEUTICS THERAPEUTIC CELL PRODUCTION CORE COMMUNICATION FORM

Document number: CF-02488-03

Revision: 03

Effective date: 06/30/2023

PLAT-07

REVISION HISTORY

REVISION HISTORY		
Effective Date	Summary of Changes	
09/11/2020	Initial version of document.	
06/21/2022	Remove calculation for Total MNC Product Volume. Update Building Cure	
	contact information. Update Organization from SCRI to SCTx.	
01/11/2023	Add an "S" to subject ID.	
06/30/2023	Remove ≥ sign from minimum target plasma volume.	
	Effective Date 09/11/2020 06/21/2022 01/11/2023	